Cancer Diagnostics Firm Nucleix Plans European Market Expansion
Executive Summary
Cancer diagnostics company Nucleix is planning to scale up commercial activities in Europe for its bladder test Bladder EpiCheck. The Israeli firm told Medtech Insight it is currently in advanced negotiations with distributors to expand the test's commercial reach.